HomepharmacySigma-tau involvement began in 2004.

Sigma-tau involvement began in 2004, felt when the company entered into a partnership with Medicines for Malaria Venture, founded the Geneva-based non-profit organization in order to discover, develop and deliver effective and affordable support antimalarial drugs through public-private partnerships, especially by the Bill & Melinda Gates Foundation and the University of Oxford.

The new data, said Claudio Cavazza, sigma-tau Chairman. Confirm the huge potential of this new combination to the gold standard in the treatment of malaria in all those countries where fatal drug – resistance has been observed with conventional antimalarials. The extremely positive results of the clinical trials, let us hope that the drug quickly obtain marketing approval. The NDA is expected the EMEA and the FDA filed in the mid-2009, so that the drug will as soon as possible as soon as possible, not only in Europe and the United States, but also in all those countries where malaria is endemic. .. The results presented in New Orleans come from a development program for the worldwide registration of medicines. The most important trials in the program were two large phase III comparative clinical trials in Africa respectively the total of approximately 2,700 patients performed 1,600 children 1,600 children under 5 years, all falciparum uncomplicated malaria due to Plasmodium falciparum, the most widespread and dangerous parasite and the cause of most of causing mortality in infected persons.Identifying and allow the detection of one significant proportion genetic risk for the shared forms of breast is the goal of on deCODE’s discovery of genes that job in breast cancer and the deCODE is cancer test. Through his know to an higher than average risk breast cancer can be and proactive changes in lifestyle in order to reduce their lifetime hazard, by ACS. These include staying physically active, maintained a healthy bodyweight, to eat healthy foods, and limiting alcohol intake and smoking.

DeCODE cancer , to modulate risk profile of the early onset of to be inherited forms for breast cancer in women tested positive for risks Varieties in the inherited BRCA1 or BRCA2 genes.